FRAILTY AND OSTEOARTHRITIS IN OLDER CHILEANS

Abstract The adverse consequences on health of frailty, make it early diagnostic very important. The coexistence of frailty with osteoarthritis, a frequent condition especially in older women, has been less studied Objective. to study the association between frailty and self-reported osteoarthritis. Methods: Cross-sectional study in994 people65 years and older (72.1%women, mean age72y±6.7) from the Alexandros cohort, designed to study disability associated with obesity in community-dwelling people60y and older living in Santiago/Chile. The frailty phenotype was defined as having ≥3 from the5 following criteria: weak handgrip dynamometry, unintentional weight loss, fatigue/exhaustion, five chair-stands/slow walking speed and low physical activity. Self-reported osteoarthritis was registered.We found a prevalence of osteoarthritis was much higher in women than in men (49.4% vs22.9%, p<0.01) Osteoarthritis was present in46.5% of frail people and30% of the robust ones (p=0.01). Frailty was present in53.3% of women with OA in and11.8% of men with OA. The crude OR for the association of frailty with Osteoarthritis was significant only for women (OR=1.43;95% CI:1.06-1.93). After sex and age adjusted logistic regression for frailty in Ostroarthritis, the OR for frailty was OR=1,39;95%IC (1,04-1,85), p=0,025, but in women with osteoarthritis the adjusted OR for frailty increase to OR=11.98 (5.637-13.23)Considering the severe consequences of frailty over health, the high burden of Osteoarthritis, its high frequency in women, and the strength of the association between both conditions, the screening for frailty is highly recommended In older women with Osteoarthritis.

We aimed to evaluate whether depressive symptoms mediated the relationship between frailty phenotype and cognitive function by sex. Frailty phenotype symptoms, cognitive function scores, and depressive symptoms were measured in 3,705 community-dwelling US adults from the Health and Retirement Study (HRS) from 20012-2016. Fried's frailty phenotype criteria (weakness, slowness, physical inactivity, low weight, and exhaustion) were used as a continuous score for frailty symptoms (0-5). Global cognition was measured by the Telephone Interview for Cognitive Status (range: 0-35). The Centers for Epidemiologic Studies-Depression Scale (CES-D) was used as a continuous measure to assess depressive symptoms (0-8). We used mediation analysis to estimate the direct and indirect effects of frailty symptoms on cognitive scores to evaluate the role of depressive symptoms as a potential mediator. Males had a larger total effect (β= -0.43; 95% CI: -0.66, -0.02; p< 0.001) for lower cognitive score for each increase in frailty symptom compared to females (β= -0.28; 95% CI: -0.47, -0.08; p=0.02), suggesting all five frailty symptoms was associated with 2.15 lower cognitive scores for males and 1.50 for females. A significant indirect effect from frailty phenotype to cognition was found through depressive symptoms for females (β= -0.03; 95% CI: -0.06, -0.00; p=0.02) but not males (β= -0.04; 95% CI: -0.08, 0.00; p=0.07). These results highlight the importance of identifying individuals with frailty and depressive symptoms to monitor and provide interventions to preserve cognitive function The adverse consequences on health of frailty, make it early diagnostic very important. The coexistence of frailty with osteoarthritis, a frequent condition especially in older women, has been less studied Objective. to study the association between frailty and self-reported osteoarthritis Methods: Cross-sectional study in994 people65 years and older (72.1%women, mean age72y±6.7) from the Alexandros cohort, designed to study disability associated with obesity in community-dwelling people60y and older living in Santiago/Chile. The frailty phenotype was defined as having ≥3 from the5 following criteria: weak handgrip dynamometry, unintentional weight loss, fatigue/exhaustion, five chair-stands/slow walking speed and low physical activity. Self-reported osteoarthritis was registered.We found a prevalence of osteoarthritis was much higher in women than in men (49.4% vs22.9%, p<0.01) Osteoarthritis was present in46.5% of frail people and30% of the robust ones (p=0.01). Frailty was present in53.3% of women with OA in and11.8% of men with OA. The crude OR for the association of frailty with Osteoarthritis was significant only for women (OR=1.43;95% CI:1.06-1.93). After sex and age adjusted logistic regression for frailty in Ostroarthritis, the OR for frailty was OR=1,39;95%IC (1,04-1,85), p=0,025, but in women with osteoarthritis the adjusted OR for frailty Innovation in Aging, 2022, Vol. 6, No. S1 increase to OR=11.98 (5.637-13.23)Considering the severe consequences of frailty over health, the high burden of Osteoarthritis, its high frequency in women, and the strength of the association between both conditions, the screening for frailty is highly recommended In older women with Osteoarthritis

INTERVENTIONS TO PREVENT THE FRAILTY IN OLDER WOMEN WITH FRAILTY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Ha Na Jeong, Sun Ju Chang, Joo Ri Kim, and Gi Won Choi, Seoul National University, Seoul, Seoult'ukpyolsi, Republic of Korea Background: Frailty is a health challenge related to adverse health outcomes in older adults. Older women are more likely to be frail than older men. However, few studies have reviewed the effectiveness of interventions for older women with frailty is scant. Objective: This systematic review aimed to explore the properties of interventions and to investigate their effectiveness in preventing the progression of frailty in older women with pre-frailty or frailty.
Methods: Narrative synthesis was conducted to identify the contents, outcome variables, and findings of the interventions. Then, a meta-analysis was performed to evaluate the effectiveness of exercise interventions on grip strength, sit-and-reach, sit-to-stand, and timed up and go tests.
Conclusion: Exercise interventions are essential to improve physical health, in particular mobility, in older women with pre-frailty or frailty. Future studies should consider theoretical frameworks and evaluate psychological and cognitive health as well as quality of life to develop and provide effective interventions to prevent the progression of frailty in older women.

BLOOD-BASED BIOMARKER CHANGES IN A PHASE 2B TRIAL ASSESSING LOMECEL-B IN OLDER ADULTS WITH FRAILTY
Kevin Ramdas 1 , Danial Mehranfard 1 , Eric Naioti 2 , Geoff Green 1 , Lisa McClain-Moss 1 , Dan Gincel 1 , Joshua Hare 1 , and Anthony Oliva 1 , 1. Longeveron Inc.,Miami,Florida,United States,2. Longeveron,Inc.,Miami,Florida,United States Aging frailty (AF) is a multidimensional geriatric syndrome that is characterized by physical and cognitive symptoms, increasing the vulnerability of affected older adults to adverse health outcomes. Mechanistically, a low-grade chronic inflammatory state (inflammaging), endothelial dysfunction, and decreased regenerative capacity are thought to be major contributors to AF pathophysiology. Lomecel-B is an allogenic medicinal signaling cell(MSC) formulation that can potentially ameliorate AF through pleiotropic mechanisms, including anti-inflammatory, pro-vascular, and proregenerative activities. We completed a Phase 2b randomized, double-blinded, placebo-controlled trial designed to assess Lomecel-B benefits for AF via change versus placebo in the six-minute walk test(6MWT), to assess the dose-response relationship, and to evaluate bioactivity via changes in bloodbased biomarkers. Enrolled subjects were aged 70-85 years with mild-to-moderate AF, a reduced 6MWT of 200-400m, and Tumor Necrosis Factor-α of ≥ 2.5pg/mL indicative of inflammaging. In total, 143 subjects received a single intravenous infusion of Lomecel-B at doses of 2.5 x 107 cells (25M, N=35), 5.0 x 107 cells (50M, N=30), 1.0 x 108 cells (100M, N=33), or 2.0 x 108 cells (200M, N=16), or placebo (N=29). Safety and efficacy assessments were performed at 1, 3, 6, and 9 months post-infusion. Increases in 6MWT and decreases in serum levels of the blood-based biomarker Soluble-Tie-2 were observed at 9 months in the Lomecel-B groups versus placebo. Notably, both observations were seen in a dose dependent fashion with 200M showing the highest effect. Based on the findings, a next-phase trial is being developed to advance this clinical program and will be presented.